Segment, Geographic and Other Revenue Information (Detail) (USD $) In Millions, unless otherwise specified	3 Months Ended
	Mar. 29, 2015		Mar. 30, 2014
Segment Reporting Information [Line Items]
Revenues	$ 10,864	[1]	$ 11,353	[1]
Earnings	3,082	[1],[2]	2,847	[1],[2]
Other Business Activities [Member]
Segment Reporting Information [Line Items]
Revenues	111	[3]	56	[3]
Earnings	(669)	[2],[3]	(667)	[2],[3]
Corporate, Non-Segment [Member]
Segment Reporting Information [Line Items]
Revenues	0	[4]	0	[4]
Earnings	(1,287)	[2],[4]	(1,200)	[2],[4]
Purchase Accounting Adjustments [Member]
Segment Reporting Information [Line Items]
Revenues	0	[4]	0	[4]
Earnings	(903)	[2],[4]	(1,008)	[2],[4]
Acquisition-related Costs [Member]
Segment Reporting Information [Line Items]
Revenues	0	[4]	0	[4]
Earnings	(23)	[2],[4]	(30)	[2],[4]
Certain significant items [Member]
Segment Reporting Information [Line Items]
Revenues	0	[5]	57	[5]
Earnings	(228)	[2],[5]	(1,016)	[2],[5]
Other unallocated [Member]
Segment Reporting Information [Line Items]
Revenues	0		0
Earnings	(41)	[2]	(105)	[2]
Reportable Segments [Member]
Segment Reporting Information [Line Items]
Revenues	10,753		11,240
Earnings	6,232	[2]	6,873	[2]
Global Innovative Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Revenues	3,075		3,076
Earnings	1,511	[2]	1,767	[2]
Global Vaccines, Oncology and Consumer Healthcare [Member]
Segment Reporting Information [Line Items]
Revenues	2,664		2,174
Earnings	1,464	[2]	1,057	[2]
Global Established Pharmaceutical [Member]
Segment Reporting Information [Line Items]
Revenues	5,014		5,990
Earnings	$ 3,256	[2]	$ 4,049	[2]

[1] Amounts may not add due to rounding.

[2] Income from continuing operations before provision for taxes on income.

[3] Other business activities includes the revenues and operating results of Pfizer CentreSource, our contract manufacturing and bulk pharmaceutical chemical sales operation, and the costs managed by our Worldwide Research and Development organization and our Pfizer Medical organization.

[4] For a description, see the “Other Costs and Business Activities” section above.

[5] Certain significant items are substantive, unusual items that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis.For Revenues in the first quarter of 2014, certain significant items represent revenues related to our transitional manufacturing and supply agreements with Zoetis. For additional information, see Notes to Consolidated Financial Statements––Note 2D. Acquisitions, Licensing Agreements, Collaborative Arrangements, Divestitures, and Equity-Method Investments: Divestitures included in our 2014 Financial Report, which was filed as Exhibit 13 to our 2014 Annual Report on Form 10-K. For Earnings in the first quarter of 2015, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $104 million, (ii) charges for business and legal entity alignment of $101 million and (iii) other charges of $23 million. For additional information, see Note 3 and Note 4.For Earnings in the first quarter of 2014, certain significant items includes: (i) charges for certain legal matters of $694 million, (ii) certain asset impairments of $114 million, (iii) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of $134 million, (iv) charges for business and legal entity alignment of $29 million and (v) other charges of $45 million. For additional information, see Note 3 and Note 4.